259 related articles for article (PubMed ID: 11791690)
1. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
Chew NY; Chan HK
J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
[TBL] [Abstract][Full Text] [Related]
2. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
Asking L; Lundbäck H; Persson B
J Aerosol Med; 2002; 15(4):435-6; author reply 436-8. PubMed ID: 12581510
[No Abstract] [Full Text] [Related]
3. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
Tarsin W; Assi KH; Chrystyn H
J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
[TBL] [Abstract][Full Text] [Related]
4. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler.
Criée CP; Meyer T; Petro W; Sommerer K; Zeising P
J Aerosol Med; 2006; 19(4):466-72. PubMed ID: 17196075
[TBL] [Abstract][Full Text] [Related]
5. Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor.
Hoe S; Young PM; Traini D
J Pharm Sci; 2011 Dec; 100(12):5270-80. PubMed ID: 21850666
[TBL] [Abstract][Full Text] [Related]
6. Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).
Zhou QT; Tong Z; Tang P; Citterio M; Yang R; Chan HK
AAPS J; 2013 Apr; 15(2):511-22. PubMed ID: 23371759
[TBL] [Abstract][Full Text] [Related]
7. In vitro testing of two formoterol dry powder inhalers at different flow rates.
Weuthen T; Roeder S; Brand P; Müllinger B; Scheuch G
J Aerosol Med; 2002; 15(3):297-303. PubMed ID: 12396417
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
Eliraz A; Ramirez-Rivera A; Ferranti P; Holzer R; García JM; Turcotte C; Rapatz G; Pfister P; Overend T; Kottakis J
Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
[TBL] [Abstract][Full Text] [Related]
9. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 microg and formoterol Aerolizer 12 microg in moderate to severe asthma: a randomised, crossover study.
Schlimmer P
Pulm Pharmacol Ther; 2002; 15(4):369-74. PubMed ID: 12220942
[TBL] [Abstract][Full Text] [Related]
10. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler.
Lötvall J; Mellén A; Arvidsson P; Palmqvist M; Radielovic P; Kottakis J; Pfister P
Can Respir J; 1999; 6(5):412-6. PubMed ID: 10572207
[TBL] [Abstract][Full Text] [Related]
11. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer.
Nielsen KG; Skov M; Klug B; Ifversen M; Bisgaard H
Eur Respir J; 1997 Sep; 10(9):2105-9. PubMed ID: 9311511
[TBL] [Abstract][Full Text] [Related]
12. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
13. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
14. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma.
Bisgaard H; Klug B; Sumby BS; Burnell PK
Eur Respir J; 1998 May; 11(5):1111-5. PubMed ID: 9648964
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
16. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
17. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
[TBL] [Abstract][Full Text] [Related]
18. Do all dry powder inhalers show the same pharmaceutical performance?
Taylor A; Gustafsson P
Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
[TBL] [Abstract][Full Text] [Related]
19. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.
Smith KJ; Chan HK; Brown KF
J Aerosol Med; 1998; 11(4):231-45. PubMed ID: 10346666
[TBL] [Abstract][Full Text] [Related]
20. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
